Efzimfotase alfa

Efzimfotase alfa (ALXN-1850) is enzyme replacement therapy agent targeting the deficiency of tissue-nonspecific alkaline phosphatase (TNSALP) . Efzimfotase alfa functions by hydrolyzing the substrates of TNSALP, reducing the concentrations of substrates such as inorganic pyrophosphate (PPi) and pyridoxal 5′-phosphate (PLP) . Efzimfotase alfa is promising for research of hypophosphatasia (HPP) [1][2].

2746354-58-3

ALXN-1850

12352203

Phosphatase

Metabolic Enzyme/Protease

Neuroscience-Neuromodulation

Cardiovascular Disease

[Efzimfotasealfa]

[1]Dahir KM, et al. Medical Management of Hypophosphatasia: Review of Data on Asfotase Alfa. Curr Osteoporos Rep. 2025 Mar 18;23 (1) :14.|[2]Dahir KM, et al. Safety, pharmacokinetics, and pharmacodynamics of efzimfotase alfa, a second-generation enzyme replacement therapy: phase 1, dose-escalation study in adults with hypophosphatasia. J Bone Miner Res. 2024 Sep 26;39 (10) :1412-1423.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P991210/

Inhibitory Antibodies

Phase 3